Mycophenolate Mofetil Tablets IP 500MG – Mofris 500 Tablets

MOFRIS 500 – For Transplant Success and Autoimmune Balance

Mofris 500 Tablets – Mycophenolate Mofetil Tablets IP 500MG belongs to the class of immunosuppressants, which includes anti-inflammatory agents and is used in the treatment of organ transplant rejection along with another immunosuppressant, as it inhibits T and B lymphocytes (a type of white blood cell that attacks foreign cells) and suppresses the production of antibodies (which identify and kill foreign cells). These effects suppress the immune system so that the transplanted graft is not rejected.

Key Benefits of Mycophenolate Mofetil Tablets IP 500MG – Mofris 500 Tablets
✅ Potent Immunosuppressive Action – Inhibits inosine monophosphate dehydrogenase (IMPDH), suppressing T- and B-lymphocyte proliferation and preventing graft rejection.
✅ Proven Efficacy in Transplant Management – Widely used and clinically validated in kidney, liver, and heart transplant recipients for long-term graft survival.
✅ Steroid-Sparing Properties – By effectively suppressing immune responses, MMF allows for reduced reliance on corticosteroids, thereby minimizing steroid-related side effects in long-term therapy.

Recommended by Specialists:
👨‍⚕️ Nephrologists: For the prevention of kidney transplant rejection and the management of lupus nephritis.
👨‍⚕️ Hepatologists & Transplant Surgeons: Used in liver and heart transplant patients to prevent graft rejection.
👨‍⚕️ Rheumatologists: Prescribed as a steroid-sparing immunosuppressant for autoimmune conditions like systemic lupus erythematosus, vasculitis, and rheumatoid arthritis (off-label).
👨‍⚕️ Neurologists: Used in refractory autoimmune neurological conditions such as myasthenia gravis and neuromyelitis optica (off-label).

INDICATIONS:
✅ Prophylaxis of Organ Transplant Rejection (Kidney, Liver, Heart)
✅ Steroid-sparing agent in chronic immunosuppressive regimens
✅ Autoimmune Disorders (Off-label: Lupus nephritis, Myasthenia gravis)